Not for the first time I was awake at 3am this morning. Cup of tea in hand, watching American football. It's amazing how those players keep the ball when so many other players are piling on top of them. Rarely do you see the thing break free. They must practice for hours.... The House of Commons … Continue reading Do I detect a slight fumble of the ball in today’s Commons Select Committee report on clinical trials?
This week, patients got a couple more options for finding out about clinical trials they can take part in. Patientslikeme (which was launched in the United States a few years ago) has unveiled its new new clinical trials site which you can find here. Patientslikeme is capturing a lot of attention here in the UK … Continue reading New websites launched for people looking to join a clinical trial; but will patients want a ‘coming together’ at some point?
The Organisation for Economic Co-operation and Development (OECD) yesterday waded into the increasingly feverish debate about the regulation of clinical trials with a strongly worded recommendation calling on its members to harmonise approval processes. The recommendation which is worded with the minimum of fuss, is backed by a more detailed explanatory memorandum. But I am … Continue reading OECD wades into clinical trials debate, but statement on public involvement goes awol
Earlier this week Patient View published the results of its annual tracker of the pharmaceutical industry's reputation among patient groups. The latest study surveyed 600 patient groups (72% of them from Europe). As well as asking patient groups to rank 29 pharmaceutical companies by various indices (such as whether their practices were patient-centred) - Lundbeck … Continue reading Patient View Report: Pharma industry’s lack of transparency harming reputation with patients
The European Medicines Agency (EMA) has published the note of the conference held in London a few weeks ago, about its plans for proactive publication of clinical trial data. It is now setting up five advisory groups and inviting self-nominations from people to join these. You will find the following listing of the advisory groups, plus … Continue reading Patients need apply – European Medicines Agency (EMA) next steps on clinical trial data
My thanks to the Diabetes Research Network (DRN) for sending me their report 'Improving public awareness of clinical research.' Clinical research networks are at the 'front-line' in terms of encouraging people to take part in research and this report gives a good insight into some of the tools and strategies used by DRN. Others trying to … Continue reading Diabetes and cancer network reports on engaging people about clinical research and more…
We do beat ourselves up on a regular basis in this country. Sometimes appropriately. But often the punches fly a little too freely. Australia have launched a new clinical trials website today to boost patient recruitment. It has strengths. But it is not as good as our own UK Clinical Trials Gateway (UKCTG). For one … Continue reading Australia launches new clinical trials website for consumers and it’s not as good as the UK’s (UKCTG)
I spoke at the Clinical Discovery 2012 conference yesterday about the future value and impact of clinical research. This is one of a number of similar events I've presented at over the last month or so. On reflection there generally seems a more 'upbeat' conversation among conference-goers about clinical research in the UK compared to this time last … Continue reading GSK’s Witty remarks are easy to swallow from a patient perspective but the rest of the flock must follow
Interesting paper from the Annals of Oncology and covered in PharmaTimes on how access to clinical trials has led to better outcomes for children with cancer. The data relates to clinical trial activity promoted by the Children's Cancer and Leukaemia Group. A direct quote from the article says: "Between 1966 and 1970 just 28% of young … Continue reading Clinical trials and children: impact on outcomes
This was reported last week in the US press but I have not seen it covered here in the UK. Pfizer has reeled-in its social media strategy for recruiting patients to a US clinical trial of over-active bladder drug, Detrol. But it hopes to come back next year with a renewed 'virtual trial strategy.' In the meantime … Continue reading Pfizer undaunted by social media hurdles in clinical trial recruitment
So, this has been fairly well-reported already. But in a show of my utmost commitment to the transparency agenda here is a link to the news release on the Royal College of Physicians (RCP website) about yesterday's launch by the Ethical Standards in Health and Life Sciences Group (ESHLSG) (a consortia of professional, medical and commercial … Continue reading Consortium publishes new principles for transparency in clinical trials/The Guardian debate on public engagement in research
I thought this short piece by David Shaywitz in US Forbes Magazine was terrific. David examines three problems identified by the pharmaceutical industry as holding them back, and proposes solutions to each. The first seems to follow on neatly from my blog on Saturday which looked at the venture philanthropy tactics being pursued by charities to … Continue reading Behavioural matters: pharma could learn its way out of its ‘slump’ by working more closely with patients
One of the many good things to come out of the establishment of the UK Clinical Research Collaboration (UKCRC) in the early noughties, is the registration of UK clinical trials units and the bringing together of these units into a network. Registration, which takes the form of an application and then review by an independent international panel … Continue reading UK clinical trials units go up for review and registration